Masavibart (ZRC3308-A7) is ananti-SARS-CoV-2 monoclonal antibody(IgG1 type). Masavibart shows good binding affinity to a non-competing epitope on theRBDof theSARS-CoV-2spike protein. Masavibart can be used in combination withZRC3308-B10(HY-145643) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease^[1].

SARS-CoV-2^[1].

Masavibart (ZRC3308-A7; 0-5×10⁵ng/mL) shows virus neutralizing ability in VeroE6/Vero CCL81 (SARS-CoV-2 infection model) cells, when in combination with ZRC3308-B10 (ratio 1:1)^[1].
Masavibart neutralizes SARS-CoV-2 variants B.1.1.7, B.1.351, B.1.617.2, and B.1.617.2 AY.1 in vitro, when in combination with ZRC3308-B10 (ratio 1:1)^[1].
Masavibart binds to the RBD of SARS-CoV-2 S1 protein^[1].

Masavibart (ZRC3308-A7; 0.5, 2.5, 25 mg/kg; 48 h prior to the SARS-CoV-2 infection) effectively prevents SARS-CoV-2 infection in syrian hamster, when in combination with ZRC3308-B10 (ratio 1:1)^[1].
Masavibart (0.5, 2.5, 25 mg/kg; i.p.; single) shows the serum levels remaines constant without much reduction for up to 7 days, in syrian hamster^[1].

2640223-84-1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.